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ABSTRACT 
 
Purpose: In Scotland, care homes provide assisted living and medical services.  
Psychotropic medications (antipsychotics, anxiolytics, and hypnotics) may be over 
utilized in these facilities.  This study compared psychotropic medication utilization in 
elderly care home residents to the equivalent population of non-care home residents.  
It is hypothesized that patients in care homes utilize psychotropic medications more 
than non-care home residents.  
Methods:  Demographic and prescription information for all patients aged 65 years 
and older on January 1, 2011 who received at least one prescription for a psychotropic 
medication during 2011 was retrieved from the national Prescribing Information 
System (PIS).  Patients were grouped into care home and non-care home populations 
and were stratified by gender and 10-year age band.  Estimates of the total non-care 
home and care home populations were made using National Records of Scotland 
information and, using PIS, by counting all individuals resident in a care home who 
had received at least one prescription of any type during 2011.  Relative risk of 
receiving psychotropics, percent of population treated, and other utilization measures 
were calculated.  Statistical significance was determined by p< 0.05 utilizing a paired 
two-sample t-test. 
Results: A total of 879,492 patients were included, 32,372 of whom resided in care 
homes (3.7%). Males comprised 28% and 43% of the care home and non-care home 
populations, respectively.  Age groups 65-74, 75-84, and 85+ made up 12%, 35%, and 
53% of the care home population, respectively, while making up 55%, 34%, and 11% 
of the non-care home population, respectively.  More care home patients were treated 
with psychotropics than non-care home patients (41.6% vs. 12.1%, p<0.05).  Men 
were more likely than women to receive psychotropics in care homes (43.6% vs. 
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40.9%, p<0.05), but less likely to receive psychotropics in the non-care home setting 
(9.4% vs. 14.3%, p<0.05).   Treatment with psychotropics was more common for 
every age group living in the care home (65-74 years Relative Risk (RR)=4.6 95% 
CI=2.93-6.29, 75-84 years RR=3.4 95% CI=2.42-4.54, 85+ years RR=2.4 95% 
CI=1.31-3.47).  The percent of non-care home patients treated with psychotropics 
increased as patients aged (65-74 years 10.7%, 75-84 years 13.4%, 85+ years 15.9%). 
Conversely, the percent of care home patients treated with psychotropics decreased as 
patients aged (65-74 years 49.4%, 75-84 years 46.0%, 85+ years 37.4%).  
Conclusion:     Residents of care homes have increased use of psychotropic 
medications compared to individuals not in care homes. There are significant 
differences in the use of psychotropic medications based on gender and age.  Whether 
this reflects appropriate prescribing warrants further investigation. 
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Background:  
 Care homes in Scotland, similar to long term care facilities in the United 
States, are designed to offer assisted living services, often with medical care, to those 
who require services beyond what they are capable of providing for themselves.  In 
Scotland, the elderly comprise around 90% of the care home population.  The elderly 
population typically has several comorbidities that influence their care and require 
multiple medication regimens to manage these comorbidities.  It is generally 
accepted, that in many instances the elderly, both in and out of care homes, are 
exposed to inappropriate medication regimens1.  This is of great concern given the 
elderly population is already at an increased risk of experiencing adverse events from 
medication use and inappropriate use increases these risks unnecessarily.           
 There is growing evidence that many of the adverse drug events that occur in 
care homes are preventable and that inappropriate medication use accounts for a 
significant portion of healthcare expenditures.  A study from 2005 in the United States 
estimated that 42% of adverse drug events in long term care facilities were 
preventable1.  It was also estimated that between 2000 and 2001, potentially 
inappropriate medication expenditures reached $7.2 billion1.  Inappropriate 
prescribing can therefore have significant medical and financial consequences. 
 For those patients who are in care homes, there are concerns that psychotropic 
medications, anxiolytics, hypnotics, and antipsychotics, may be used in inappropriate 
ways such as a chemical restraint or sedative.  Though anxiolytics, hypnotics, and 
antipsychotics only comprise a subset of the medications that are considered to be 
used inappropriately in elderly patients in care homes, they are drugs that carry side 
effect profiles that can be very problematic in this population.  A study of nursing 
home residents in the United States showed that psychotropic medications in 
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particular, have significant influence on the physical functioning of residents taking 
psychotropic medications versus those residents who where not including increasing 
the risk of falls which can be particularly problematic in the elderly population2.  
Also, studies have shown that the use of antipsychotics in patients with dementia may 
increase risk of death up to one and a half times3.  But, not only can the patients 
physical functioning be affected, psychotropic medications can significantly alter the 
mental functioning of these patients as well.   
 Given the nature of these medications and the impact they can have on the 
given population, recommendations and regulations have been passed both in the U.S. 
and in Scotland to try to reduce the exposure to these types of medications in the 
elderly population.  The Centers for Medicare and Medicaid Services in the U.S. have 
regulations and recommendations on the use of High Risk Medications (HRM’s), 
including many psychotropic medications, in elderly patients.  In the United 
Kingdom, there have been national recommendations to reduce the use of a variety of 
psychotropic medications in elderly patients.  With the notion of possible 
inappropriate use of psychotropic medications in the elderly and care home residents 
along with the push to reduce or control the use of HRMs, including many 
psychotropics, in elderly patients, the purpose of this study was to use the Prescribing 
Information System (PIS) data warehouse to examine the use of anxiolytics, 
hypnotics, and antipsychotics in those patients 65 years of age or older and to 
compare this with use in the equivalent population not in care homes.  It is 
hypothesized that patients in care homes utilize psychotropic medications more than 
non-care home residents. 
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Prescribing Information System 
 The PIS data warehouse, housed within the information services division 
(ISD) of the National Health Service (NHS) National Services Scotland (NSS), is a 
national database for Scotland which houses community prescription data dating back 
to 1993. It currently houses nearly 1.3 billion community prescription events.  This 
system tracks all prescription events for patients in the community, including those in 
care homes.  A unique patient identifier (UPI) has been attached to the prescribing 
data since 2009.  This UPI is unique to each patient in Scotland.  The inclusion of the 
UPI number in the data allows for linking of prescription events for an individual as 
well as linking of prescription events for a population based on patient specific 
prescription information such as gender, care home residency, and age.  Since 2009, 
nearly 95% of the data captured relating to anxiolytics, hypnotics, and antipsychotics 
has been captured with a UPI.  This recently included identifier was instrumental in 
the following study, allowing for the capture of nearly all prescription events based on 
set criteria designed in the database queries. 
 
Methods:  
The program Business Object XI WebIntelligence™ was used to retrieve data 
from the PIS data warehouse.  This program was used to query the data warehouse 
and pull data specific to set parameters outlined in the queries.  The queries were 
designed to retrieve data on those patients who were 65 years of age or older on 
January 1, 2011 and who had been given a prescription for an anxiolytic, hypnotic, or 
antipsychotic medication, as defined in the British National Formulary (BNF) under 
codes 4.1.1, 4.1.2, and 4.2.1 (Appendix A.), during 2011.  The BNF groups and codes 
medications based on therapeutic use or pharmacology and uses an organizational 
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system of chapters, sections, and sub-sections that provides a unique code for each 
drug.  For each individual who was captured in the above criteria, the following data 
was extracted: care home residency status, age, gender, NHS board of residency 
(Appendix B), type of psychotropic medication received, and the number of 
prescriptions received.  Then, from these data, the percent of population treated with a 
psychotropic medication, number of psychotropic medication prescriptions per treated 
patient, and number of prescriptions per 1000 population were calculated.  
Furthermore relative risk (RR), or treatment ratios, (the percent treated in the defined 
care home population divided by the percent treated in the defined non-care home 
population) and prescription frequency per treated patient ratios (the prescriptions per 
treated patient in the defined care home population divided by the prescriptions per 
treated patient in the defined non-care home population) were calculated for the care 
home population versus the non-care home population.  The treatment ratios, 
prescription frequency per treated patient ratio, and other measures of utilization were 
constructed for the nation as well as for the 14 health boards.  These calculations were 
performed using Business Object XI WebIntelligence™  and Microsoft Excel™. 
 Using Microsoft Excel™ statistical comparisons were made for psychotropic 
medication utilization, primarily between those patients resident in care homes and 
those not resident in care homes based on the utilization measures stated above.  
Comparisons were made based on gender (male and female) and 10 year age group 
bands (65-74, 75-84, 85+).  Using the UPI, patients were counted into these various 
groups based on the outlined criteria and distinct counts were made for the nation as 
well as for each health board. The counts and comparisons were made for the whole 
of Scotland as well as by each individual health board. Analysis was repeated for 
anxiolytics, hypnotics, and antipsychotics individually as well as collectively as 
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psychotropics as a whole.  Statistical significance was determined by a p value less 
than 0.05 utilizing a paired two-sample t-test. 
Population Estimates 
In order to appropriately measure and compare the data, population estimates 
were constructed for both the care home population and the non-care home population 
who were age 65 or older.  Because there was no readily available census data for the 
total care home population, the population estimate was made by counting the number 
of individuals aged 65 or older, in care homes, who received a prescription of any 
type.  This count was made for the whole of Scotland as well as distinct counts by 
health board, gender, and 10 year age band. 
The population estimate for those not in care homes was made using the mid-
year population estimate from 2010 by the National Records of Scotland (NRS) for 
those age 65 or older and again this estimate was made for the whole of Scotland as 
well as distinct counts by health board, gender, and 10 year age band.  From this mid-
year estimate the estimated care home population from above was subtracted to yield 
the estimated population of persons not in care homes.  The 2010 NRS estimate was 
used because it is the most recent estimate available. 
 
Results: 
 A total of 879,492 patients were included, 32,372 of whom resided in care 
homes (3.7%). Males comprised 28% and 43% of the care home and non-care home 
populations, respectively.  Age groups 65-74, 75-84, and 85+ made up 12%, 35%, and 
53% of the care home population, respectively, while making up 55%, 34%, and 11% 
of the non-care home population, respectively. 
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 For psychotropic medications as a whole, the percent treated for those patients 
in a care home for the whole of Scotland was 41.6% while the percent treated for 
those not in a care home was 12.1% (Table 1).  This yields a treatment ratio of 3.4 and 
a prescription frequency per treated patient ratio of 1.6 for the care home population 
versus the non-care home population (Table 2).  When divided by health board, each 
board follows a similar pattern (Figure 1).   
 Population 
Description 
Prescription 
Type  
Percent of Care 
Home Population 
Treated 
Percent of Non-Care 
Home Population 
Treated 
Total ^ All* 41.6 12.1 
Total ^ Anxiolytic 17.0 5.2 
Total^ Hypnotic 16.1 6.8 
Total^ Antipsychotic  23.2 1.8 
Female All* 40.9 14.3 
Male All* 43.6 9.4 
Age 65-74 All* 49.4 10.7 
Age 75-84 All* 46.0 13.4 
Age 85+ All* 37.4 15.9 
Table 1. Percent treated with a psychotropic medication in the care home and non-
care home populations broken down by population description of those over the age 
of 65 and by type of psychotropic prescription  
*Prescription type of ‘All’ is defined as a prescription for any type of psychotropic 
medication (anxiolytic, hypnotic, or antipsychotic) 
^Population description of ‘Total’ is defined as all those age 65 years or older within 
the given population regardless of age or gender. 
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Care Home 
Population 
Description 
Prescription 
Type 
Treatment Ratio 
(Relative Risk) 
Prescription 
Frequency per 
Treated Patient 
Ratio 
Total ^ All* 3.4 1.6 
Total ^ Anxiolytic 3.3 1.4 
Total^ Hypnotic 2.4 1.3 
Total^ Antipsychotic  12.9 1.3 
Female All* 2.9 1.5 
Male All* 4.6 1.8 
Age 65-74 All* 4.6 2.0 
Age 75-84 All* 3.4 1.7 
Age 85+ All* 2.4 1.3 
Table 2. Treatment and prescription frequency per treated patient ratios for specific 
psychotropic medications for the distinct care home populations versus the distinct 
non-care home population 
*Prescription type of ‘All’ is defined as a prescription for any type of psychotropic 
medication (anxiolytic, hypnotic, or antipsychotic) 
^Population description of ‘Total’ is defined as all those age 65 years or older within 
the given population regardless of age or gender. 
 
 
Figure 1. Percent of patients treated with any anxiolytic, hypnotic, or antipsychotic in 
2011 delineated by health board and compared across the care home population and 
non-care home population. 
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 Similar patterns are observed with the anxiolytic medication class.  The 
percent treated for those patients in a care home for the whole of Scotland was 17.0% 
while the percent treated for those not in a care home was 5.2% (Table 1).  This yields 
a treatment ratio of 3.3 and the prescription frequency per treated patient ratio of 1.4 
for the care home population versus the non-care home population (Table 2).  When 
divided by health board, each board follows a similar pattern (Figure 2). 
 
 
Figure 2. Percent of patients treated with an anxiolytic in 2011 delineated by health 
board and compared across the care home population and non-care home population. 
 
Similar patterns are observed with the hypnotic medication class.  The percent 
treated for those patients in a care home for the whole of Scotland was 16.1% while 
the percent treated for those not in a care home was 6.8% (Table 1).  This yields a 
treatment ratio of 2.4 and the prescription frequency per treated patient ratio of 1.3 for 
the care home population versus the non-care home population (Table 2).  When 
divided by health board, each board follows a similar pattern (Figure 3). 
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Figure 3. Percent of patients treated with a hypnotic in 2011 delineated by health 
board and compared across the care home population and non-care home population. 
 
Similar patterns are observed with the antipsychotic medication class.  The 
percent treated for those patients in a care home for the whole of Scotland was 23.2% 
while the percent treated for those not in a care home was 1.8% (Table 1).  This yields 
a treatment ratio of 12.9 and the prescription frequency per treated patient ratio of 1.3 
for the care home population versus the non-care home population (Table 2).  When 
divided by health board, each board follows a similar pattern (Figure 4). 
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Figure 4. Percent of patients treated with an antipsychotic in 2011 delineated by 
health board and compared across the care home population and non-care home 
population. 
 
When examining the utilization measures of prescriptions per treated patient 
and prescriptions per 1000 population, similar patterns are observed as those seen in 
the percent of population treated.  These data are displayed in Table 3. 
Population 
Description 
Prescription 
Type 
Prescriptions 
per treated 
patient in 
care home 
Prescriptions 
per treated 
patient non-
care home 
Prescriptions 
per 1000 
care home 
population  
Prescriptions 
per 1000 
non-care 
home 
population 
Total^ All* 11 6.9 4605 1043 
 
Total^ Anxiolytic 6.0 4.4 1008 237 
 
Total^ Hypnotic 8.6 6.6 1370 467 
 
Total^ Antipsychotic 9.2 6.9 2332 128 
 
Female All* 11 7.1 4492 1028 
 
Male All* 11.3 6.3 4925 604 
 
65-74 All* 13.5 6.6 6852 718 
 
75-84 All* 11. 7.0 5296 942 
 
85+ All* 9.9 7.4 3706 1188 
 
Table 3. Prescriptions per treated patient and prescriptions per 1000 population for 
specific psychotropic medications for the distinct care home populations and the 
distinct non-care home population 
*Prescription type of ‘All’ is defined as a prescription for any type of psychotropic 
medication (anxiolytic, hypnotic, or antipsychotic) 
^Population description of ‘Total’ is defined as all those age 65 years or older within 
the given population regardless of age or gender. 
 
When examining gender and care home residency status for the whole of 
Scotland and for psychotropic medications combined, females in care homes had a 
percent treated of 40.9%, men in care homes had a percent treated of 43.6%, females 
not in care homes had a percent treated of 14.3%, and males not in care homes had a 
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percent treated of 9.4% (Figure 5) (Table 1).  This yields a treatment ratio of 2.9 and a 
prescription frequency per treated patient ratio of 1.5 for females in the care home 
population versus the non-care home population.  This yields a treatment ratio of 4.6 
and a prescription frequency per treated patient ratio of 1.8 for males in the care home 
population versus the non-care home population (Table 2). 
 
 
Figure 5. Percent of patients treated with any anxiolytic, hypnotic, or antipsychotic in 
2011 delineated by care home status and gender 
 
When looking at age band and care home residency status for the whole of 
Scotland and for psychotropic medications combined, those ages 65-74 in a care 
home had a percent treated of 49.4%, those ages 75-84 in a care homes had a percent 
treated of 46.0%, those ages 85+ in a care home had a percent treated of 37.4%, those 
ages 65-74 not in a care home had a percent treated of 10.7%, those ages 75-84 not in 
a care homes had a percent treated of 13.4%, and those ages 85+ not in a care home 
had a percent treated of 15.9% (Figure 6) (Table 1).  This yields a treatment ratio of 
4.6 and a prescription frequency per treated patient ratio of 2.0 for those ages 65-74 in 
the care home population versus the non-care home population.  This yields a 
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treatment ratio of 3.4 and a prescription frequency per treated patient ratio of 1.7 for 
those ages 75-84 in the care home population versus the non-care home population.  
This yields a treatment ratio of 2.4 and a prescription frequency per treated patient 
ratio of 1.3 for those age 85+ in the care home population versus the non-care home 
population (Table 2). 
 
  
Figure 6. Percent of patients treated with any anxiolytic, hypnotic or antipsychotic 
medication in 2001 by care home status and 10 year age band. 
 
 
Discussion:   
For psychotropic medications as a whole one can see there is a tremendous 
amount more prescription utilization in the care home population than in the non-care 
home population.  Statistically significant differences were found in the percent of 
patients treated with any anxiolytic, hypnotic or antipsychotic between the care home 
population and the non-care home population (p-value<0.05).  This difference is seen 
across all health boards as depicted in Figure 1.  Combining all health boards, the 
treatment ratio, seen in Table 2, for the care home population versus the non-care 
home population is 3.4, meaning that holding all else constant a patient in a care home 
has a 3.4 fold increase in their percent chance of being treated with a psychotropic 
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medication than a patient not in a care home.  The prescription frequency per treated 
patient ratio for all of Scotland shows that patients in a care home treated with a 
psychotropic medication receive 1.6 times as many medications as those treated who 
are not in a care home.  
When analyzing the data based on specific drug class, anxiolytic, hypnotic, or 
antipsychotic, in the total care home population, similar results are seen as those 
derived when looking at the psychotropic medications as a whole.  The percent treated 
for each drug class is higher in the care home population and in all three cases the 
difference is statistically significant (p-value<0.05). 
Similarly, the prescriptions per treated patient and prescriptions per 1000 
population for all population descriptions analyzed were significantly higher in the 
care home population than in the non-care home population (p-value<0.05).  Again, 
these utilization measures display increased use of psychotropics in the care home 
population that may be due to variety of factors included in the limitations of this 
study or due to overuse in the care homes. 
When examining gender in the care home and non-care home populations, 
similar patterns as above in regard to percent treated, prescriptions per treated patient, 
and prescriptions per 1000 population are seen between the care home and non-care 
home population for like genders.  Analysis of males versus females and percent 
treated in the care home population and percent treated in the non-care home 
population reveals more intriguing details.   Females in the care home had less 
percentage treated than did males in the care home but had more percentage treated 
than males in the non-care home population.  The difference in percent treated 
between males and females in the care home population was statistically significant 
(p-value<0.05) as well as the difference between males and females not in care 
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homes.  Though it may be considered that males are more prone to be diagnosed with 
disease states requiring psychotropic medications, there is no available diagnosis data 
for the population.  If this were the case and was part of the reason males were 
admitted to care homes then one would expect to see the differences seen between 
males and females in the care home and non-care home population.  But, again, 
without diagnosis data the differences between males and females is hard to fully 
analyze. 
 When comparing the age bands in the care home and non-care home, the same 
patterns as above in regards to percent treated, prescriptions per treated patient, and 
prescriptions per 1000 population are seen between the care home and non-care home 
population for like age bands.  Treatment with psychotropics was more common for 
every age group living in the care home with relative risk as follows, 65-74 years 
RR=4.6 95% confidence interval (CI)=2.93-6.29, 75-84 years RR=3.4 95% CI=2.42-
4.54, 85+ years RR=2.4 95% CI=1.31-3.47.  Those patients in a care home ages 65-74 
and those ages 75-84 had a significantly higher percent of patients treated with any 
psychotropic medication than those in a care home age 85+ (p-value<0.05).  Though 
the percent of patients treated with any psychotropic medication was higher in the 
care home population age 65-74 than in the care home population age 75-84, this 
difference was not statistically significant (p-value>0.05).  When looking at the non-
care home population by age band, the age band 75-84 and age band 85+ populations 
had significantly higher percent of patients treated with any anxiolytic, hypnotic, or 
antipsychotic medications than the age 65-74 population (p-value<0.05).  Also, the 
age 85+ population had a significantly higher percent of patients treated than the age 
75-84 population for the non-care home population (p-value<0.05) (Figure 6.) (Table 
1).  
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 Some interesting trends are found when comparing age band to age band 
within the care home population and then in the non-care home population.  One 
would expect utilization of psychotropic medications to increase as age increases due 
to the notion of increased disposition to disease states requiring psychotropic 
medications such as antipsychotics as an individual gets older4.  This trend is 
confirmed in the non-care home population, but the care home population shows the 
opposite.  In the care home population, as the age band age increases the utilization of 
psychotropic medications decrease.  These differences may be explained by changes 
in the population demographics as patients age.  As one moves from one age band to 
another in increasing order, based on the NRS census, the proportion of males who 
make up that particular age band decreases.  This is seen both in and out of the care 
homes.  Therefore, with decreasing proportion of male representation in increasing 
age bands and evidence that a higher percentage of males are treated with a 
psychotropic medication in care homes, one would expect to see the decreasing 
percent of over all percent of patients treated in the care home population as age band 
increases. And, since the percent treated of females not in the care home is higher 
than the percent treated of males not in the care home and there is a decreasing 
proportion of males in the increasing age bands, one would expect to see the 
increasing percent of over all percent of patients treated in the non-care home 
population as age band increases. 
Limitations 
 Though the presented data provides evidence suggestive of increased 
utilization of psychotropic medications in the elderly care home populations, there are 
still several limitations that must be noted.  The primary limitation with this study is 
the inherent differences in the care home and non-care home populations that may 
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dictate the necessity for use of a psychotropic medication.  Differences may be 
present between those patients in care homes and those not in care homes such that 
those patients in care homes have a higher diagnosis rate of disease states that require 
these medications, such as dementia, agitation, anxiety, etc.  This data is not linked 
with the prescribing data used in this study and thus this influence could not be 
described.  The days of treatment per prescription were not standardized.  In this 
study, one prescription of a psychotropic medication is equal to another prescription 
of a psychotropic medication regardless of days supply or strength of the medication. 
 The method by which the care home population was calculated makes the 
assumption that there is an insignificant amount of individuals who were resident in a 
care home who received zero prescriptions during their stay.  Given that prescriptions 
in care homes not only include standard medications but also a vast array of medical 
supplies, this was believed to be reasonable assumption.  Using the 2010 NRS census 
estimate assumes an insignificant change in population from 2010 to 2011 with 
regards to psychotropic medication utilization.  Due to the UPI capture rate, the data 
presented only represents approximately 95% of all data available and we cannot 
account for the influence of the remaining 5% of the data.  Prescribing habits of 
prescribers may differ from region to region or NHS board to NHS board and 
influence the levels of psychotropic medications prescribed.  Medication availability 
may differ from board to board, due to accessibility of rural health boards throughout 
the country, and dictate utilization of one medication over another out of necessity.  
Males and females may have a different diagnosis rate for disease states that require 
psychotropic medications that would dictate utilization of these medications.  These 
limitations must be considered when drawing conclusions about the data. 
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Further Analysis 
 With this analysis as a foundation, additional analysis can be undertaken to 
further compare the care home population to the non-care home population.  Further 
analysis of individual health boards may provide insight into the variations within 
each board and allow for comparison against national data.  The data could be 
examined based on deprivation categories, which are based on socio-economic 
factors, providing information on patients socioeconomic statuses and psychotropic 
medication utilization.  Further analysis on multiple psychotropic medication 
utilization could be done (e.g. concomitant use of anxiolytic and hypnotic, hypnotic 
and antipsychotic, etc.).  This methodology could be undertaken with a variety of 
other drug classes to analyze utilization in the care homes.  Other medication classes 
that may be of interest are antibiotics, medications for pain management, or 
medications for chronic conditions to explore the prevalence of comorbidities in the 
care home population. 
 
Conclusion:   
 Care homes are designed to assist the elderly and provide skilled medical 
treatments to their patients. For those patients who are in care homes, there are 
concerns that psychotropic medications, anxiolytics, hypnotics, and antipsychotics, 
are over utilized and/or used in inappropriate ways.  Though this study presented does 
not indicate causality, the data presented shows an increase in psychotropic 
medication use in those patients in care homes over those not in care homes. There are 
significant differences in the use of psychotropic medications based on gender and 
age as well.  With the rapidly growing elderly population, it is prudent that 
appropriate medication utilization be on the forefront of patient care. 
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Appendix A.  
 
List of drugs included under BNF codes 4.1.1 (hypnotics), 4.1.2 (anxiolytics), and 
4.2.1 (oral antipsychotics) 
 
HYPNOTICS: (BNF 4.1.1) 
• BENZODIAZEPINES 
O NITRAZEPAM 
O FLURAZEPAM 
O LOPRAZOLAM 
O LORMETAZEPAM 
O TEMAZEPAM 
• ZALEPLON, ZOLPIDEM, AND ZOPICLONE 
O ZALEPLON 
O ZOLPIDEM TARTRATE 
O ZOPICLONE 
• CHLORAL AND DERIVATIVES 
O CHLORAL HYDRATE 
• CLOMETHIAZOLE 
• ANTIHISTAMINES 
O PROMETHAZINE HYDROCHLORIDE 
• ALCOHOL 
• SODIUM OXYBATE 
• MELATONIN 
 
ANXIOLYTICS: (BNF 4.1.2) 
• BENZODIAZEPINES 
O DIAZEPAM 
O ALPRAZOLAM 
O CHLORDIAZEPOXIDE HYDROCHLORIDE 
O LORAZEPAM 
O OXAZEPAM 
• BUSPIRONE 
• MEPROBAMATE 
 
ANTIPSYCHOTICS: (BNF 4.2.1) 
• FIRST-GENERATION ANTIPSYCHOTIC DRUGS 
O BENPERIDOL 
O CHLORPROMAZINE HYDROCHLORIDE 
O FLUPENTIXOL 
O HALOPERIDOL 
O LEVOMEPROMAZINE 
O PERICYAZINE 
O PERPHENAZINE 
O PIMOZIDE 
O PROCHLORPERAZINE 
O PROMAZINE HYDROCHLORIDE 
O SULPIRIDE 
O TRIFLUOPERAZINE 
O ZUCLOPENTHIXOL 
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O ZUCLOPENTHIXOL ACETATE 
• SECOND-GENERATION ANTIPSYCHOTIC DRUGS 
O AMISULPRIDE 
O ARIPIPRAZOLE 
O CLOZAPINE 
O OLANZAPINE 
O PALIPERIDONE 
O QUETIAPINE 
O RISPERIDONE 
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Appendix B. 
The 14, regionally defined, health boards of Scotland and corresponding health board 
code 
 
Health Board Health Board Code 
NHS Ayrshire and Arran A 
NHS Borders B 
NHS Dumfries and Galloway Y 
NHS Fife F 
NHS Forth Valley V 
NHS Grampian N 
NHS Greater Glasgow and Clyde G 
NHS Highland H 
NHS Lanarkshire L 
NHS Lothian S 
NHS Orkney R 
NHS Shetland Z 
NHS Tayside  T 
NHS Western Isles W 
 
